<DOC>
	<DOC>NCT02215954</DOC>
	<brief_summary>To demonstrate non inferiority of a) "FE 999169 Split Dosing Schedule" (one dose on the day before and the second dose on the day of colonoscopy) and b) "FE 999169 Day Before Dosing Schedule" (two doses on the day before colonoscopy) to " Niflec On the Day Dosing Schedule" in subjects requiring colonoscopy.</brief_summary>
	<brief_title>A Phase III Study With FE 999169 Versus Niflec for Colon Cleansing</brief_title>
	<detailed_description />
	<criteria>Japanese patients, age 20 to 80 years inclusive, requiring colonoscopy Female patients should be postmenopausal (women â‰¥45 years with no menstrual period for at least 12 months without an alternative medical cause), or be surgically sterile, or be using medically approved contraception, throughout the trial period. Fertile female patients must have a confirmed negative pregnancy test at screening and randomization Patients must have had more than or equal to 3 spontaneous bowel movements per week prior to the colonoscopy Written informed consent obtained prior to any studyrelated procedure Acute surgical abdominal conditions, such as acute intestinal obstruction or intestinal perforation, diverticulitis, appendicitis. If intestinal obstruction and perforation are suspected, perform appropriate diagnostic studies to rule out these conditions Active (acute/exacerbation of/severe/uncontrolled) Inflammatory Bowel Disease (IBD) Any prior colorectal surgery, excluding appendectomy, haemorrhoid surgery or prior endoscopic procedures Colon disease (history of colonic cancer, toxic megacolon, idiopathic pseudoobstruction, hypomotility syndrome) Gastrointestinal disorder (active ulcer, outlet obstruction, retention, gastroparesis, ileus) Upper gastrointestinal surgery (gastric resection, gastric banding, gastric bypass) Uncontrolled angina and/or Myocardial Infarction (MI) within last 3 months, Congestive Heart Failure (CHF), or uncontrolled hypertension Renal insufficiency (any of the serum creatinine, or serum potassium value exceeding the upper limits of the normal range at screening) or a history of this event Participation in any other clinical trial during the past 3 months Any clinically significant laboratory value at screening, including preexisting electrolyte abnormality, based on clinical history that the investigators feel may affect the study evaluation Hypersensitivity to active ingredients Subject who cannot suspend the prohibited medications Subjects not appropriate to participate in the study as deemed by the investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>